Targets › EGF
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2028.
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. (UniProt, P01133)
Open in Phaseline: the race on EGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Henry Ford Health System | uhCG/EGF Combination of urinary-derived human chorionic gonadotropin and epidermal growth factor | EGF | Phase 1 | Graft Versus Host Disease | Nov 2028 |
Graft Versus Host Disease (1)
small molecule (1)
Henry Ford Health System (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.